

CALCIUM

HOMEOSTASIS

Hormones in charge of Calcium Homeostasis

→ parathyroid hormone

peptide
low MW
 $t_{1/2} \rightarrow \sim 25 \text{ min}$
no binding protein

① maintain normal serum Ca^{2+} level

↳ Bone: ↑ osteoclastic activity \Rightarrow ↑ Ca^{2+} mobilisation

Kidney: ↑ Ca^{2+} reabsorption

GIT: ↑ Ca^{2+} absorption

② ↓ Serum PO_4^{3-} level

↳ inhibit $\text{Na}^+ - \text{PO}_4^{3-}$ co-transporter

↓ PO_4^{3-} reabsorption from PCT


↓ PO_4^{3-} serum level

potentially wastes PO_4^{3-} in urine

③ Act on both osteoblastic & osteoclastic activity

marker: ALP

marker: Urinary hydroxyproton
(degradation product of collagen)




→ excreted through kidney

free Ca^{2+} never deposits on kidney


PO_4^{3-} excreted \rightarrow No $\text{Ca}_3(\text{PO}_4)_2$ formed

No ↓ chance of deposition

• thus **PTH** → hypercalcemic
hypophosphatemic



Note: In hyperparathyroidism, \uparrow PTH \rightarrow \uparrow serum Ca^{2+}
 \downarrow
 sensed by CASR
 Predictive mechanism \rightarrow \uparrow Ca^{2+} excretion
 thus, \uparrow PTH can not cause (generally) hypercalcemia
 and in hyperparathyroidism, urinary Ca^{2+} level \uparrow es
 although PTH \uparrow es Ca^{2+} reabsorption (due to CASR in kidney)



<u>PTH level</u>	<u>actⁿ on Osteoblast</u>	<u>actⁿ on osteoclast</u>	<u>functⁿ</u>
physiological/normal	⊕	⊕	bone remodelling
hyperparathyroidism (↑↑ level)	⊕⊕	⊕⊕⊕⊕	bone destruction
Intermittent low dose of PTH (teriparatide)	⊕⊕⊕	⊕	bone protection

→ **Vit D** → can stimulate osteoblast → ↑ bone formation

↳ don't produce RANK Ligand → No Osteoclastic activity

↳ ↑ Ca²⁺ absorption from GIT

↳ ↑ Ca²⁺, PO₄³⁻ reabsorption

↓

serum ↑ Ca²⁺, ↑ PO₄³⁻ level

→ **Calcitonin** → inhibit osteoclastic activity

↓

↓ Serum Ca²⁺ level
also ↓ PO₄³⁻ level

	Ca ²⁺ (serum)	PO ₄ ³⁻
PTH	↑	↓
Vit D	↑	↑
Calcitonin	↓	↓

Osteoclast have only calcitonin receptors.

↳ NO PTH & Vit D receptors.

Directly acting on Osteoclast → • Calcitonin
 (Inhibition) • Bisphosphonates (drug)
 • Osteoprotegerin (natural)

IL-6, Microphage activating protein (MAP) → Multiple myeloma


can directly activate osteoclast → lytic lesions

(bind to RANK Receptor and inhibit binding of RANK Ligand
 do not stimulate osteoclast
 bone protection)

* Denosumab (monoclonal antibody drug similar to osteoprotegerin)

Only substance directly activating osteoblast and inhibiting Osteoclast is - Strontium

Action of Bisphosphonates



↳ Normal osteoclast bone resorption function.

↓ Carbonic anhydrase ⇒ ↓ osteoclastic activity ⇒

thick, weak bone

↓
Osteopetrosis

↓ bone matrix ⇒ Osteoporosis

1st generation bisphosphonate \Rightarrow gets incorporated in bone matrix

Etidronate
Tiludronate
not used anymore

\downarrow
osteoclast can't identify bone

• camouflage effect

2nd generation / NO_3^- containing bisphosphonate

Pamidronate
(i.v./oral)
 \rightarrow needs no dose adjustment \bar{c} renal failure

Risedronate (oral)

\downarrow
encourage osteoclast to take up the bisphosphonate

\downarrow
Inhibit & becomes toxic to osteoclast

\downarrow
osteoclast lifespan reduces

3rd generation bisphosphonate

\rightarrow highly potent

Alendronate (oral)
Zoledronate (i.v.) } - needs dose adjustment \bar{c} renal failure

S/E of bisphosphonate - hypocalcemia

pill induced Esophagitis
(C/I - GERD)

Kidney Injury - nephropathy
(C/I - Renal failure)^{EKD}

Aseptic osteonecrosis of jaw

* femur fracture (Paradoxical)
↳ subtrochanteric
(on long term use)


uses of Bisphosphonate - Osteoporosis

- Hypercalcemia of malignancy
- Bone metastasis.

Advise -

- lot of water \bar{c} pills to avoid sticking at GIT
- do not lie down for 1-2 hrs.

CALCIUM



1g albumin binds to 0.8 mg of calcium.

Corrected calcium = Serum Ca^{2+} + 0.8 [4 - albumin]

Example \Rightarrow serum Ca^{2+} = 7.5 mg%
albumin = 2 mg%
~~2~~

$$\begin{aligned} \text{calcium} &= 7.5 + 0.8 \times [4 - 2] \\ &= 9.1 \text{ mg\%} \end{aligned}$$

\hookrightarrow normal but appear hypocalcemic due to low albumin

Hypercalcemia


Mild 10.5/11 - 12 mg%.

Moderate 12 - 13.5 mg%.


Severe > 13.5 mg%.

↳ M/c cause - malignancy

Test → Intact PTH



Mechanism Hypercalcemia of Malignancy



In lymphoma, sarcoidosis activation of **1 α -OHase** in macrophage (normally + vit D) that helps in \uparrow 1,25-cholecalciferol \rightarrow \uparrow Ca²⁺ absorptⁿ from gut

dietary vit D \triangleright (N)
active vit D \triangleright (U)

TREATMENT of Hypercalcemia

i.v. fluid (hypercalcemia induce dehydration, kidney injury, polyuria)

A
B
C

↓
TOC → Bisphosphonate (to reduce calcium level)
pamidronate (i.v.)

↳ at emergency condition because requires no dose adjustment

Zoledronate

↳ c/I - CKD

other options - Calcitonin
Denosumab

Adjuvant therapies - Steroids

↳ lymphoma,
granulomatous
condition

useful in
PTH mediated

cinacalcet → calcimimetic
↓
stimulate CASR
↓
reduce PTH

↓
if cancer is diagnosed,
then proper therapy
should be done

Primary Hyperparathyroidism

Cause → parathyroid adenoma
→ parathyroid carcinoma
(very rare)

sporadic
m/c site - @ inferior
parathyroid gland

familial
MEN1
MEN2A
(multiglandular)

clinical features . commonly asymptomatic
if symptomatic - m/c - renal stones
→ abdominal groans
Peptic ulcer
→ psychic moans.

Investigation →

$\uparrow \text{Ca}^{2+}$ → $\uparrow \text{iPTH}$ → urinary calcium \uparrow

supports 1° hyperparathyroidism

4DCT, USG, MIBI scan to localize which gland is problematic

Uniglandular

observe or surgery

Indication

- age < 50y
- screen $Ca^{2+} > 11 \text{ mg/dL}$
- Renal failure (eGFR - 60 ml/min)
- Osteoporosis (Tscore -2.5)

Minimally invasive parathyroidectomy

Multiglandular
[test for MEN]

surgery is only option
Total/subtotal parathyroidectomy


if +nt, treatment extend.


little part of gland
can be implanted
in forearm - under
brachioradialis
muscle
leg - tibialis anterior
muscle

X-Ray - lytic lesion - m/c - radial side of middle phalanx


- 24 hr urinary $Ca^{2+} > 100 \text{ mg/dL}$
- FECA < 0.01 → FHH

ECG change in hypercalcemia-

- Short QT 
- \pm J waves
(Osbourne waves)
- ST change



Clinical Feature - Neuromuscular irritability
Bone problems
↳ Trousseau sign
tetany



ECG change - long QT
 (can lead to torsade des pointes)


Treatment - i.v. calcium gluconate (1-2g) stat
 in CODE situation, calcium chloride
 central line has to be chosen

↳ for severe patient

for mild/moderate case - oral calcium carbonate
 citrate

Vit D

Disease	S. Ca ²⁺	S. PO ₄ ³⁻	ALP	PTH
↓ HPT	↑	↓	↑	↑
Malignancy (PTH rP)	↑	↓	↑	↓ (PTH related peptide ↑ (m/c - squamous cell cancer of lung)
Malignancy (lytic)	↑	↑/N	N	↓ (m/c - breast & lung cancer)
Dietary Vit D toxicity	↑	↑/N	(N)/↑	↓ (25HCC ↑)
Sarcoidosis	↑	N	N	↓ (↑ 1-α-OHase) (1,25 HCC ↑, 25HCC ↓)



Clinical feature -

- short stature
- round face
- brachydactyly (4th - 5th metacarpal)
- ↳ Knuckle Knuckle dimple dimple sign

Pseudopseudo hypoparathyroidism

(N) (N) (N) (N)

- ↳ Normal biochemical profile
- abnormal bone remodelling
- ↳ Basal ganglia calcification

differentiating
c Vit D def.



CKD



(↓ 1,25 D Hcc)

Osteoporosis



(matrix deficiency)
DXA scan req